Delivery Order SPE2DB24D2205-SPE2DB25FEFJA
- Not listed
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $40,681.37 firm fixed price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This non-set-aside contract will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued...
- The Defense Logistics Agency awarded a $22,077.35 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $20,568.10 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 18, 2025, with completion targeted for August 19, 2025. This is a firm fixed price, non-set-aside contract for pharmaceutical delivery to support federal medical procurement needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $23,540.52 on August 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units), with an ultimate completion date of August 19, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania. The award represents a child order issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $24,779.66 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price, competitively awarded contract—not utilizing any set-aside designation—will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEFJADelivery Order
The Defense Logistics Agency awarded a $20,290.04 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 24, 2025, with completion scheduled for July 25, 2025. This is a firm fixed price, non-set-aside contract performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. The Dupixent product—a specialty biologic medication used to treat conditions such as atopic dermatitis, moderate-to-severe eczema, and certain asthma indications—represents the type of specialized pharmaceutical commodity that AmerisourceBergen regularly delivers through its DLA contracts. The award reflects the company's demonstrated capability to fulfill federal medical supply requirements through open competition and its role as a preferred provider within the DLA's pharmaceutical supply chain for supporting Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.3k | 7/24/25 |